Studies show preeclampsia condition affects around seven percent of the pregnant women in the United States. Earlier studies show preeclampsia increases the risk of high blood sugar glucose levels (type 2 diabetes T2D), high blood pressure, heart diseases and stroke. A study supported by the National Institutes of Health, Maryland, United States and done by Penn State researchers shows lifelong cardiovascular disease risks with pregnancy preeclampsia condition in women.
Researchers in their studies compared to blood vessels functioning among women who had preeclampsia and no preeclampsia during their pregnancies. Researchers have observed permanent dysfunction of blood vessels (change in the way blood vessels function) in those pregnant women who had pregnancy preeclampsia condition. Due to this permanent change in the functioning of blood vessels, those women face lifelong higher cardiovascular disease risks, even though they recovered from preeclampsia after giving birth. Researchers say their findings will help in developing better treatment options for the prevention of cardiovascular diseases.
Author of the study was Anna E. Stanhewicz, Department of Kinesiology, Pennsylvania State University. The study findings were published on September 12, 2017, in the Hypertension. Title of the article was "Increased Angiotensin II Sensitivity Contributes to Microvascular Dysfunction in Women Who Have Had Preeclampsia."
Postmenopausal women with breast cancer is being treated with aromatase inhibitors (AIs) drugs. But there are doubts whether aromatase inhibitors (AIs) increases risks to cardiovascular diseases.
A study done by researchers from Princess Margaret Cancer Center, Toronto, Canada and the University of Toronto, Canada shows increased risk of bone fractures and heart diseases such as heart attack, cardiovascular diseases, angina and heart failure with an extended or long-term usage of aromatase inhibitors (AIs) drugs in early breast cancer treatment.
The current study was conducted among 16,349 patients. The study results show an increased unfavorable effect on cardiovascular health, bone fractures and treatment discontinuation with a long-term aromatase inhibitors (AIs) drug treatment. Their study also shows increased risk with aromatase inhibitors (AIs) drugs compared to tamoxifen drug in the treatment of breast cancer in women patients. The following table shows the quantum of health diseases risks with aromatase inhibitors (AIs) drugs.
But researchers could not find out whether the risk reduction is due better protective tamoxifen drug effect or adverse risk is due to adverse aromatase inhibitors (AIs) drugs.
Author of the study was Dr. Eitan Amir, MB, ChB, Ph.D, senior fellow, Medical Oncologist, Princess Margaret Hospital, Toronto, Canada. The study findings were published on August 4, 2017, in the Journal of the National Cancer Institute. Title of the article was "Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis."
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.